• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kirk McDonald Appointed to Ziff Davis Board of Directors

    11/16/23 4:35:00 PM ET
    $ELAN
    $ZD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ELAN alert in real time by email

    Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising.

    "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis."

    McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when it was a division of AT&T. He was also President of Pubmatic, and has held executive level leadership roles at Time Inc., the Aquantive division of Microsoft, and CNET Networks. McDonald currently serves on the board of Elanco (NYSE:ELAN), and is a founding member of the Black Executive CMO Alliance. He also serves on the boards of directors of industry organizations including the Ad Council (as co-chair), the Paley Center for Media, and the Advertising Week Advisory Council. An alumnus of the City College of New York, Mr. McDonald majored in English as an undergraduate.

    "Kirk is widely respected in our industry, and has been a leader and innovator across a range of companies in the media and advertising ecosystem," said Ziff Davis CEO Vivek Shah.

    "I am delighted to be joining the Ziff Davis Board of Directors," McDonald said. "I look forward to working with Vivek and the entire Ziff Davis team across its portfolio of leading brands."

    About Ziff Davis

    Ziff Davis (NASDAQ:ZD) is a vertically focused digital media and internet company whose portfolio includes leading brands in technology, shopping, gaming and entertainment, connectivity, health, cybersecurity, and martech. For more information, visit www.ziffdavis.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231116449936/en/

    Get the next $ELAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAN
    $ZD

    CompanyDatePrice TargetRatingAnalyst
    Ziff Davis Inc.
    $ZD
    4/22/2025$33.00Overweight → Neutral
    Analyst
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2024$18.00Buy
    UBS
    Elanco Animal Health Incorporated
    $ELAN
    12/2/2024$14.00Market Perform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    Ziff Davis Inc.
    $ZD
    5/2/2024$70.00Neutral → Overweight
    JP Morgan
    Elanco Animal Health Incorporated
    $ELAN
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    Elanco Animal Health Incorporated
    $ELAN
    12/19/2023$17.00Buy
    Jefferies
    Elanco Animal Health Incorporated
    $ELAN
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ELAN
    $ZD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:57 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:28 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/22/25 5:21:32 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    $ZD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Ziff Davis to Participate in One Investor Conference in May

      Ziff Davis, Inc. (NASDAQ:ZD) today announced its participation in one investor conference in May. Details of the conference are as follows: J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference Location: The Westin Boston Seaport District, Boston, MA Date and time: May 14, 2025, 4:20 pm (ET) Webcast: https://jpmorgan.metameetings.net/events/tmc25/sessions/313256-ziff-davis-inc/webcast?gpu_only=true&kiosk=true About Ziff Davis Ziff Davis (NASDAQ:ZD) is a vertically focused digital media and internet company whose portfolio includes leading brands in technology, shopping, gaming and entertainment, health and wellness, connectivity, cybersecurity, and martech. F

      4/28/25 7:00:00 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ziff Davis Inc.

      SC 13G/A - ZIFF DAVIS, INC. (0001084048) (Subject)

      11/12/24 5:57:23 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • Amendment: SEC Form SC 13G/A filed by Ziff Davis Inc.

      SC 13G/A - ZIFF DAVIS, INC. (0001084048) (Subject)

      11/4/24 2:15:05 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • SEC Form SC 13G filed by Ziff Davis Inc.

      SC 13G - ZIFF DAVIS, INC. (0001084048) (Subject)

      10/31/24 11:55:01 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kretzmer W Brian bought $25,029 worth of Common Stock $0.01 Par Value (653 units at $38.33), increasing direct ownership by 5% to 12,968 units (SEC Form 4)

      4 - ZIFF DAVIS, INC. (0001084048) (Issuer)

      3/6/25 6:01:33 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Elanco Animal Health Incorporated

      10-Q - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 9:05:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 6:30:46 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ziff Davis Inc.

      DEFA14A - ZIFF DAVIS, INC. (0001084048) (Filer)

      3/27/25 4:57:42 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Leadership Updates

    Live Leadership Updates

    See more
    • Ziff Davis Appoints John Ingram as SVP, Corporate Finance and Development

      Ziff Davis, Inc. (NASDAQ:ZD), has named John Ingram Senior Vice President, Corporate Finance and Development, overseeing global activities related to mergers and acquisitions and working with corporate leadership on strategic planning, capital allocation, capital markets transactions, and stakeholder engagement. He will report to Bret Richter, Chief Financial Officer of Ziff Davis. Mr. Ingram brings more than 18 years of M&A and corporate finance experience with a focus on the media and technology sectors. Prior to joining Ziff Davis, Mr. Ingram co-founded Aliri Capital, an independent sponsor focused on investing in lower middle market B2B services and tech-enabled services companies. Be

      4/21/25 9:00:00 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • Ziff Davis to Announce First Quarter 2025 Earnings

      Ziff Davis, Inc. (NASDAQ:ZD) will release its First Quarter 2025 Earnings at 6:00PM ET on Thursday, May 8, 2025. Additionally, Ziff Davis invites the public, members of the press, the financial community, stockholders, and other interested parties to listen to a live audio Webcast of its First Quarter 2025 Earnings Call at 8:30AM ET on Friday, May 9, 2025. Vivek Shah, Chief Executive Officer, and Bret Richter, Chief Financial Officer, will host the call. Materials presented during the call will be posted on the Company's web site at ziffdavis.com and furnished as an exhibit to the Company's 8-K filed with the Securities and Exchange Commission pursuant to Regulation FD in connection with t

      4/17/25 7:00:00 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • Everyday Health Group Acquires Leading Digital Media Property theSkimm

      theSkimm to Join Everyday Health, LoseIt!, BabyCenter, and Other EHG Brands Everyday Health Group, a division of Ziff Davis, Inc. (NASDAQ:ZD), today announced the acquisition of theSkimm, a leading media brand and suite of products delivering high-value content to millions of millennial and Gen Z female readers. Co-founded in 2012 by then-news producers Danielle Weisberg and Carly Zakin, theSkimm was launched as an email newsletter. From there, it has grown into a suite of products reaching millions of multi-generational women today, serving as a trusted source to help them live their smartest lives by seamlessly integrating into their existing routines. theSkimm now includes the Daily Sk

      3/19/25 4:05:00 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications

    $ELAN
    $ZD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ziff Davis downgraded by Analyst with a new price target

      Analyst downgraded Ziff Davis from Overweight to Neutral and set a new price target of $33.00

      4/22/25 7:23:44 AM ET
      $ZD
      Telecommunications Equipment
      Telecommunications
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    $ZD
    Financials

    Live finance-specific insights

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ziff Davis Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

      Ziff Davis, Inc. (NASDAQ:ZD) ("Ziff Davis" or "the Company") today reported unaudited financial results for the fourth quarter and year ended December 31, 2024. "We believe 2024 marked an inflection point for the Company as it returned to revenue, adjusted diluted EPS, and free cash flow growth," said Vivek Shah, Chief Executive Officer of Ziff Davis. "We are also excited to introduce a new segment reporting structure that we believe will aid investors in gaining a better understanding and appreciation of our business." FOURTH QUARTER 2024 RESULTS Q4 2024 quarterly revenues increased 5.9% to $412.8 million compared to $389.9 million for Q4 2023. Income from operations decreased t

      2/24/25 6:00:00 PM ET
      $ZD
      Telecommunications Equipment
      Telecommunications